4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall St set for lower open as oil gains on Mideast uncertainty, eyes on Trump-Xi talks
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- Plug Power COO resigns to join another company
- Wall Street ends down as oil prices, Treasury yields rise
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Anthropic's Claude AI identifies novel enzyme system in DNA search
Goldman Sachs Reinstates 4D Molecular Therapeutics (FDMT) at Buy, 'Platform value to inflect via 2024 catalysts'
February 7, 2024 4:53 AM EST(Updated - February 7, 2024 5:21 AM EST)
Goldman Sachs analyst Salveen Richter reinstates coverage on 4D Molecular Therapeutics (NASDAQ: FDMT) with a Buy rating and a price target of $81.00.
The analyst comments "Given positive Ph2 intravitreal gene therapy 4D-150 data in wet age-related macular degeneration (wAMD), and the planned Ph3 initiation in 1Q25, we move from Not... More
